Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Bullboard Posts
Comment by Leafs4Lifeon Apr 10, 2018 1:31pm
136 Views
Post# 27860555

RE:RE:Revenue projection - a million bucks in 3 weeks or less

RE:RE:Revenue projection - a million bucks in 3 weeks or lessDo you have any evidence to suggest that LDS will generate $30 to $40 in revenue per gram or are you just spitballing? 

I came to my estimates by looking at what high end resin sells for in the market and then splitting the retail price in half (basically a 100% markup for the retailer).  Is it your conclusion that LDS will be making low level resin or do you think the retailers are going to get an even bigger cut of their high end product?  I'm honestly curious, because if you've got a good reason for that estimate I'm all ears.

I rewatched the AGM last night because I remembered Brad discussing the Live Resin products. Around the 55 minute mark he dicusses LDS making "the highest level live resin" and he says that competitors who make similar products have retail value of "$150 to $200 per gram."  I don't know how LDS ends up with $30 to $40 in revenue per gram if the retail price is $150 or higher. 

Watch it for yourself if you don't believe me



johnmeds wrote: I think Q2 will be the first significant revenue for the company.  They should start ramping production from the 15,000 grams per month level in April and start the sales of CannaStrips.   

Some of the Feb and March production of resine will go into producing the CannaStrips.  In terms of your revenue estimates - I believe they sell to the dispensaries in the $30 to $40 per gram level. 

Just want to level set and make sure there is no disappointment in the Q1 numbers. 

This will be a great long term busienss that is going about thinks the correct way (licenses, testing).  It will likely be a $300 million ($2.50 to $3.00 per share) business once they hit their stride not a $75 mil business ($0.75 per share).

A bunch of near term warrants at $0.75 that will bring more money into the company.     


Bullboard Posts